When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Eli Lilly & Co. will set up a S$42 million ($31 million) digital health innovation hub in Singapore, expanding its research ...

Eli Lilly logo is shown on one of the company's offices in San ... The new investment, which will bring the company's cumulative investment in China to exceed 20 billion yuan ($2.81 billion), aims to ...

As Chief Commercial Officer at Zoetis, Jamie Brannan will lead an evolved commercial organizational structure that will ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

US pharmaceutical company Eli Lilly brings Memory Cafe to its booth at the ongoing 7th CIIE in collaboration with the ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

On Thursday, Truist Securities adjusted its stock price target for Eli Lilly (NYSE:LLY) shares, bringing it down slightly to $1,029 from the previous $1,033 while still maintaining a Buy rating on ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical ...